Female Pattern Hair Loss Study | AllerVie Clinical Research, Birmingham, Alabama
Female Pattern Hair Loss Research

Phase 3 Clinical Research

Help Advance Research for Female Pattern Hair Loss

Researchers are studying whether an investigational oral tablet may help women with female pattern hair loss.

See If You Qualify

Local Study

Birmingham, AL

Oral Tablet

Non-Hormonal

13-Month Study

11 In-Person Visits

Women Enrolling

Ages 18 - 65

About the Study

This is a Phase 3 clinical research study taking place at AllerVie Clinical Research in Birmingham, Alabama. Researchers are studying whether an investigational oral tablet may help women with female pattern hair loss (also called androgenetic alopecia, or AGA). The tablet is not a hormone-based treatment.

The study is randomized and placebo-controlled, meaning some participants will receive the investigational tablet and others will receive a placebo (an inactive tablet with no medicine). Participants are assigned to a group by chance, similar to a coin flip, and neither participants nor study staff will know which group a participant is in. This Phase 3 study is registered with the U.S. National Institutes of Health at ClinicalTrials.gov (NCT07146022) and is part of a larger national program enrolling 500+ women across the United States.

What to Expect

  • 11 in-person health assessments and scalp visits over approximately 13 months

  • Scalp photography and hair measurements to track progress

  • Questionnaires completed in English regarding hair coverage and quality of life

  • Consistency in maintaining your hair length, style, color, and hair care routine

  • Placement of a small micro-dot tattoo in a clipped scalp area for accurate measurement tracking

Hair loss study participation

Who can participate?

Women ages 18 to 65.

Have a diagnosis of mild to moderate androgenetic alopecia (female pattern hair loss) from a healthcare provider.

Are in generally good health, with adequate kidney and liver function.

Are able to swallow an oral tablet and read/complete questionnaires in English.

Live within driving distance of the Birmingham, Alabama study site and are able to attend all 11 required in-person visits.

Are willing to maintain the same hair length, style, color, and care routine for the duration of the study.

Are willing to have a small area of hair clipped and a micro-dot tattoo placed in that area for scalp photography tracking.

Must NOT have uncontrolled blood pressure, a history of orthostatic hypotension, or certain heart/thyroid conditions.

Must NOT have hair loss caused by other conditions (e.g., alopecia areata, scarring alopecia).

Must NOT have recent significant weight changes or use GLP-1 medications (such as semaglutide or tirzepatide).

Must NOT have been diagnosed with COVID-19 within the past 16 weeks or have a history of prior scalp radiation.

Must NOT have used hormone replacement therapy, hormonal modulators, oral hair growth medications, or systemic retinoids within the past 6 months.

Must NOT have undergone scalp procedures (PRP injections, microneedling, laser treatments) within the past 6 months.

Must NOT have used topical hair growth treatments (such as topical minoxidil), calcium channel blockers, beta blockers, corticosteroids, ketoconazole, cimetidine, or diazoxide within the past 12 weeks.

Compensation

Participants will receive reimbursement for time and travel. There is no cost to participate, and health insurance is not required.

Click below to see if you qualify

See If You Qualify

FAQ

Researchers are studying an investigational oral tablet to learn more about its effects in women with female pattern hair loss. This Phase 3 research may help scientists better understand this condition and potential options for the future.

As part of the study's hair measurement process, participants agree to a small micro-dot tattoo on the scalp. This tiny mark helps researchers measure the same area of the scalp consistently across all visits. This requirement must be agreed to before you can enroll, and the study team will explain the process in full during screening.

This is a blinded study, which means that neither you nor the study staff will know whether you are receiving the investigational tablet or a placebo during the study. This is a standard and important part of how clinical research works.

Yes. Participation is completely voluntary. You may withdraw at any time without affecting your medical care or any relationship with your healthcare provider.